Form 4: TransMedics Director James R. Tobin Reports Acquisition of Restricted Stock Units

TransMedics Group, Inc. Director James R. Tobin has reported the acquisition of 2,134 restricted stock units (RSUs) on May 22, 2025, as part of his compensation.

Summary

• James R. Tobin, a Director of TransMedics Group, Inc. (TMDX), acquired 2,134 shares of common stock on May 22, 2025.
• These shares were acquired at a price of $0, indicating they are restricted stock units (RSUs) where each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Mr. Tobin directly beneficially owns 4,059 shares of common stock.
• Additionally, he indirectly beneficially owns 155,146 shares through the James R. Tobin 2012 Trust and 18,000 shares through The Tobin 2024 Family Trust.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is a positive sign of alignment between management and shareholder interests, as the director's compensation is tied to the company's performance. It's a routine compensation event, not a major market moving announcement, hence a moderately positive score.

Positives

• The acquisition of Restricted Stock Units (RSUs) by Director James R. Tobin aligns his interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The grant of RSUs at a $0 price is a common form of equity compensation for directors, indicating ongoing commitment and incentivization.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes, specifically an equity grant to a director. It does not provide broader industry context or trends for the medical device or organ transplant industry in which TransMedics operates.

Related Party Transactions

• The acquisition of 2,134 restricted stock units by Director James R. Tobin is a transaction between the company and a related party (an insider), representing a form of compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

TransMedics Group Inc, TMDX, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership